MA
NAUT icon

MYDA Advisors’s Nautilus Biotechnolgy NAUT Stock Holding History

MYDA Advisors’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-76,413
Closed -$55.4K – 195
2025
Q2 		$55.4K Buy
+76,413
New +$57.4K 0.01% 139

Other funds holding NAUT

ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $2.32B AUM 30.12% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.01B AUM 2.93% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MYDA Advisors's NAUT Position: Q3 2025 in Review

MYDA Advisors sold out of Nautilus Biotechnolgy (NAUT) in Q3 2025, closing a stake of 76,413 shares — an estimated $55.4K sold.

MYDA Advisors first reported a position in NAUT in Q2 2025 and held it in 1 quarter. The position peaked at $55.4K in Q2 2025. 68 funds tracked by Wall St. Rank hold NAUT as of Q3 2025.

  • MYDA Advisors reported no remaining Nautilus Biotechnolgy position as of Q3 2025 after selling out during the quarter.
  • MYDA Advisors sold 76,413 Nautilus Biotechnolgy shares in Q3 2025, an estimated $55.4K.
  • MYDA Advisors first reported a position in Nautilus Biotechnolgy in Q2 2025 and held it in 1 quarter.
  • MYDA Advisors's Nautilus Biotechnolgy position peaked at $55.4K in Q2 2025.
  • 68 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q3 2025.

Based on MYDA Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.